In January 2019, we acquired a majority interest in Regentys Corporation, a Florida corporation, a development-stage regenerative medicine company. Since its formation in May 2013 as Asana Medical Inc., Regentys has been developing a first-in-class tissue engineered therapies for the treatment of Ulcerative Colitis (UC) and other inflammatory bowel diseases.
Company profile
Ticker
GNBTQ
Exchange
Website
CEO
Joseph Moscato
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Generex Pharmaceuticals, Inc. • o 1097346 Ontario, Inc. • NuGenerex Immuno-Oncology, Inc. • Nugenerex Diagnostics, Inc. • o Rapid Medical Diagnostics Corporation • GNBTELC, LLC • Olaregen Therapeutix, Inc. • Regentys Corporation • Nugenerex Management Services, Inc. • o Nugenerex Distribution Solutions 2, LLC ...
IRS number
820490211
GNBTQ stock data
Latest filings (excl ownership)
SEC STAFF ACTION
SEC staff action: Order
10 Oct 23
SEC STAFF ACTION
SEC staff action: Order
10 Oct 23
REVOKED
Registration or securities revoked
30 Jan 23
NT 10-K
Notice of late annual filing
1 Nov 21
8-K
Other Events
23 Jul 21
8-K
Entry into a Material Definitive Agreement
21 Jul 21
10-Q
2021 Q3
Quarterly report
21 Jun 21
NT 10-Q
Notice of late quarterly filing
14 Jun 21
8-K
Other Events
12 May 21
8-K
Other Events
29 Apr 21
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G
Generex Biotechnology Corp
29 Nov 19
3
Mark Joseph SE Prioletti
11 Sep 19
3
Lawrence Anthony Salvo Sr
14 May 19
4
Harold Gray Haines
14 Dec 18
4
Harold Gray Haines
14 Dec 18
SC 13G/A
Generex Biotechnology Corp
6 Nov 18
SC 13G/A
Generex Biotechnology Corp
6 Nov 18
4
Andrew Ro
15 Oct 18
4
Richard David Jr. Purcell
15 Oct 18
Financial summary
| Quarter (USD) | Apr 21 | Jan 21 | Oct 20 | Jul 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jul 20 | Jul 19 | Jul 18 | Jul 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.68 mm | 1.68 mm | 1.68 mm | 1.68 mm | 1.68 mm | 1.68 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 2.12 mm | 2.86 mm | (no burn) | 197.36 k |
| Cash used (since last report) | n/a | n/a | 89.56 mm | 120.72 mm | n/a | 8.33 mm |
| Cash remaining | n/a | n/a | -87.89 mm | -119.04 mm | n/a | -6.66 mm |
| Runway (months of cash) | n/a | n/a | -41.4 | -41.6 | n/a | -33.7 |
Institutional ownership, Q2 2024
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|